Tempest Therapeutics公布TPST-2003在Redeem-1期1/2a试验中的积极中期数据

美股速递
Mar 30

Tempest Therapeutics公司近日披露了其核心候选药物TPST-2003在Redeem-1期1/2a临床试验中取得的中期分析结果,数据显示出令人鼓舞的疗效信号。该阶段性成果不仅验证了药物的作用机制,更为后续临床开发提供了关键依据。研究人员指出,这些积极数据将加速推进TPST-2003在肿瘤治疗领域的应用探索。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10